Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Severe Covid-19 occurred in 30 participants, with one fatality all 30 were in the placebo group.
Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. person-years 95% confidence interval, 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56. More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline.
#Marc fisher alisa trial
The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2.
Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications.
0 kommentar(er)
